An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization

Vaccine

Volumn 32, Issue 48, 2014, Pages 6485-6492

  Raghunandan, Rama ^a   Lu, Hanxin ^a   Zhou, Bin ^a   Xabier, Mimi Guebre ^a   Massare, Michael J ^a   Flyer, David C ^a   Fries, Louis F ^a   Smith, Gale E ^a   Glenn, Gregory M ^a  

^a NOVAVAX INC   (United States)

Author keywords

Baculovirus; Cotton rat; Motavizumab; Nanoparticles; Palivizumab; Respiratory syncytial virus; Sf9 cells; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; NANOPARTICLE; PALIVIZUMAB; PALIVIZUMAB COMPETING ANTIBODY; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS F PROTEIN NANOPARTICLE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; VIRUS FUSION PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; COTTON RAT; DRUG EFFICACY; DRUG POTENCY; FEMALE; HISTOPATHOLOGY; IMMUNOGENICITY; INSECT CELL; LOWER RESPIRATORY TRACT; LUNG PARENCHYMA; NONHUMAN; NOSE MUCOSA; PASSIVE IMMUNIZATION; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SF9 CELL LINE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BLOOD; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; LUNG; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SERODIAGNOSIS; SIGMODONTINAE; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; FEMALE; IMMUNIZATION, PASSIVE; LUNG; NANOPARTICLES; NEUTRALIZATION TESTS; PALIVIZUMAB; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SF9 CELLS; SIGMODONTINAE; VACCINATION; VACCINES, INACTIVATED; VIRAL FUSION PROTEINS; VIRAL LOAD;

EID: 84908577110     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.09.030     Document Type: Article

References (50)

1. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163:693-698.
2. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759.
3. Carbonell-Estrany X., Simoes E.A., Dagan R., Hall C.B., Harris B., Hultquist M., et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010, 125:e35-e51.
4. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543-546.
5. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
6. Iwane M.K., Edwards K.M., Szilagyi P.G., Walker F.J., Griffin M.R., Weinberg G.A., et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004, 113:1758-1764.
7. Ranmuthugala G., Brown L., Lidbury B.A. Respiratory syncytial virus-the unrecognised cause of health and economic burden among young children in Australia. Commun Dis Intell Q Rep 2011, 35:177-184.
8. Centers for Disease Control and Prevention RSVFAQ, update October 17, 2008.
9. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J Am Med Assoc 2003, 289:179-186.
10. Stockman L.J., Curns A.T., Anderson L.J., Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012, 31:5-9.
11. Fairchok M.P., Martin E.T., Chambers S., Kuypers J., Behrens M., Braun L.E., et al. Epidemiology of viral respiratory tract infections in a prospective cohort of infants and toddlers attending daycare. J Clin Virol 2010, 49:16-20.
12. Nair H., Simoes E.A., Rudan I., Gessner B.D., Azziz-Baumgartner E., Zhang J.S., et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 2013, 381:1380-1390.
13. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011, 239:149-166.
14. Groothuis J.R., Hoopes J.M., Hemming V.G. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 2011, 28:110-125.
15. Wu H., Pfarr D.S., Johnson S., Brewah Y.A., Woods R.M., Patel N.K., et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007, 368:652-665.
16. 2010 MBD. Motavizumab briefing document; 2010. p. 1-147.
17. Huang K., Incognito L., Cheng X., Ulbrandt N.D., Wu H. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol 2010, 84:8132-8140.
18. Glenn G.M., Smith G., Fries L., Raghunandan R., Lu H., Zhou B., et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013, 31:524-532.
19. Techaarpornkul S., Barretto N., Peeples M.E. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol 2001, 75:6825-6834.
20. Sullender W.M. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 2000, 13:1-15. [table of contents].
21. Ulbrandt N.D., Ji H., Patel N.K., Barnes A.S., Wilson S., Kiener P.A., et al. Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus. J Gen Virol 2008, 89:3113-3118.
22. Piedra P.A., Cron S.G., Jewell A., Hamblett N., McBride R., Palacio M.A., et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 2003, 21:2448-2460.
23. Luchsinger V., Piedra P.A., Ruiz M., Zunino E., Martinez M.A., Machado C., et al. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis 2012, 54:905-912.
24. Escobar G.J., Masaquel A.S., Li S.X., Walsh E.M., Kipnis P. Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy. BMC Pediatr 2013, 13:97.
25. Smith G., Raghunandan R., Wu Y., Liu Y., Massare M., Nathan M., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLOS ONE 2012, 7:e50852.
26. Calder L.J., Gonzalez-Reyes L., Garcia-Barreno B., Wharton S.A., Skehel J.J., Wiley D.C., et al. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 2000, 271:122-131.
27. Chaiwatpongsakorn S., Epand R.F., Collins P.L., Epand R.M., Peeples M.E. Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer. J Virol 2011, 85:3968-3977.
28. McLellan J.S., Correia B.E., Chen M., Yang Y., Graham B.S., Schief W.R., et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol 2011, 409:853-866.
29. Swanson K.A., Settembre E.C., Shaw C.A., Dey A.K., Rappuoli R., Mandl C.W., et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 2011, 108:9619-9624.
30. Prince G.A., Curtis S.J., Yim K.C., Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001, 82:2881-2888.
31. Prince G.A., Jenson A.B., Hemming V.G., Murphy B.R., Walsh E.E., Horswood R.L., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol 1986, 57:721-728.
32. Arbiza J., Taylor G., Lopez J.A., Furze J., Wyld S., Whyte P., et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 1992, 73(Pt 9):2225-2234.
33. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
34. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176:1215-1224.
35. Beeler J.A., van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989, 63:2941-2950.
36. Lopez J.A., Bustos R., Orvell C., Berois M., Arbiza J., Garcia-Barreno B., et al. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 1998, 72:6922-6928.
37. Blanken M.O., Rovers M.M., Molenaar J.M., Winkler-Seinstra P.L., Meijer A., Kimpen J.L., et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013, 368:1791-1799.
38. Sigurs N., Aljassim F., Kjellman B., Robinson P.D., Sigurbergsson F., Bjarnason R., et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010, 65:1045-1052.
39. Siber G.R., Leombruno D., Leszczynski J., McIver J., Bodkin D., Gonin R., et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1994, 169:1368-1373.
40. Andabaka T., Nickerson J.W., Rojas-Reyes M.X., Rueda J.D., Bacic Vrca V., Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013, 4:CD006602.
41. Gill M.A., Welliver R.C. Motavizumab for the prevention of respiratory syncytial virus infection in infants. Expert Opin Biol Ther 2009, 9:1335-1345.
42. McLellan J.S., Chen M., Leung S., Graepel K.W., Du X., Yang Y., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013, 340:1113-1117.
43. Tapia L.I., Shaw C.A., Aideyan L.O., Jewell A.M., Dawson B.C., Haq T.R., et al. Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas. PLOS ONE 2014, 9:e90786.
44. Thwaites C.L., Beeching N.J., Newton C.R. Maternal and neonatal tetanus. Lancet 2014, 10.1016/S0140-6736(14)60236-1.
45. Guvenel A.K., Chiu C., Openshaw P.J. Current concepts and progress in RSV vaccine development. Expert Rev Vaccines 2014, 13:333-344.
46. Groothuis J.R., King S.J., Hogerman D.A., Paradiso P.R., Simoes E.A. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998, 177:467-469.
47. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89:405-421.
48. Blanco J.C., Boukhvalova M.S., Shirey K.A., Prince G.A., Vogel S.N. New insights for development of a safe and protective RSV vaccine. Hum Vaccin 2010, 6:482-492.
49. Munoz F.M., Piedra P.A., Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003, 21:3465-3467.
50. Murphy B.R., Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988, 26:1595-1597.